Soleno Therapeutics
NASDAQ · SLNO·Redwood City, CA·Mid-cap·Approved
Commercial-stage rare disease company. Lead product VYKAT XR (diazoxide choline extended-release) is an FDA-approved once-daily oral therapy for hyperphagia in Prader-Willi syndrome. Pending acquisition by Neurocrine Biosciences (announced April 2026).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Soleno Therapeutics February 2026 Corporate Presentation | Corporate overview | February 18, 2026 | 22 |